Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Key Points
The study focuses on a first-in-class CDK2/4/6 inhibitor PF-06873600 for treating breast cancer.
The evaluation revealed dose-limiting toxicities (DLTs) by organ class in patients receiving this therapy.
Participants in the evaluable analysis set were monitored for adverse effects related to the treatment.
Findings may guide future research on combination therapies in breast cancer management.
Abstract
Summary of DLT by system organ class and preferred term (all causalities). DLT—evaluable analysis set.
Like
Bookmark
Share
Like
Bookmark
Share
Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer | Synapse